Medtronic Onyx Frontier™ Zotarolimus-Eluting Coronary Stent System - HSA Registration DE0509010
Access comprehensive regulatory information for Medtronic Onyx Frontier™ Zotarolimus-Eluting Coronary Stent System in the Singapore medical device market through Pure Global AI's free database. This CLASS COM medical device is registered under HSA registration number DE0509010 and owned by Medtronic, Inc. The device was registered on March 01, 2024.
This page provides complete registration details including product owner information, registrant details, importer information, and regulatory compliance data from the official Singapore HSA medical device database. Pure Global AI offers free access to Singapore's complete medical device registry, helping global MedTech companies navigate HSA regulations efficiently.
The Onyx Frontier stent system is intended for use in patients eligible for percutaneous transluminal coronary angioplasty (PTCA) with a reference vessel diameter of 2.0 mm to 5.0 mm. The stent is indicated for the treatment of the following patient and lesion subsets: • Diabetes mellitus • Multivessel disease • Acute coronary syndrome (ACS) • Acute myocardial infarction (AMI) • Unstable angina (UA) • Bifurcation lesions • In-stent restenosis (ISR) • Chronic total occlusions (CTO) • Total occlusions (TO) • Left main (LM) • Small vessel (SV) • One month of dual anti-platelet therapy (DAPT) in high bleeding risk (HBR) patients, including patients unable to tolerate long term DAPT

